Merck KGaA

Merck KGaA to buy gene therapy tools maker for $600M
BioPharma Dive
Thu, 05/23/24 - 09:37 pm
Merck KGaA
M&A
MilliporeSigma
Gamma Biosciences
gene therapy
Merck KGaA unit avoids DOJ prosecution after exposing scheme to divert drugs to China
Fierce Pharma
Wed, 05/22/24 - 10:22 pm
Merck KGaA
MilliporeSigma
DOJ
China
Merck KGaA's CDMO unit continues to slide but company sees an uptick coming
Fierce Pharma
Wed, 05/15/24 - 10:50 pm
Merck KGaA
CDMOs
Germany's Merck breaks ground on $321m biomanufacturing center
BioProcess International
Thu, 04/25/24 - 05:57 pm
Merck KGaA
drug manufacturing
Germany
Merck KGaA signs $1.4B biobuck deal with Caris to expand ADC pipeline
Fierce Biotech
Thu, 04/4/24 - 11:17 am
Merck KGaA
oncology
antibody-drug conjugates
Caris Life Sciences
Merck KGaA's MilliporeSigma drops €300M on Korean biologics plant with plans to create 300 new jobs
Fierce Pharma
Thu, 03/21/24 - 06:39 pm
Merck KGaA
South Korea
drug manufacturing
MilliporeSigma
Despite pharma growth, Merck KGaA's CDMO slowdown plays into company's overall sales decline
Fierce Pharma
Sun, 03/10/24 - 08:40 pm
Merck KGaA
earnings
CDMOs
Merck KGaA bets on Inspirna’s colorectal cancer drug ompenaclid
Pharmaphorum
Thu, 01/4/24 - 10:09 am
Merck KGaA
Inspirna
colorectal cancer
ompenaclid
Merck KGaA’s BTK Inhibitor Fails Phase III Multiple Sclerosis Studies
BioSpace
Wed, 12/6/23 - 10:44 am
Merck KGaA
evobrutinib
clinical trials
relapsing multiple sclerosis
MS
Merck KGaA buys into Abbisko’s late-stage joint tumor med for $70M upfront
Fierce Biotech
Tue, 12/5/23 - 11:07 am
Merck KGaA
Abbisko Therapeutics
pimicotinib
joint tumors
Merck KGaA's pharma unit joins the healthcare migration to Boston's Seaport innovation hub
Fierce Pharma
Tue, 11/14/23 - 09:59 pm
Merck KGaA
Boston
biotech hubs
Merck KGaA pays $169M for selective PARP1 drug, stepping up challenge to AstraZeneca and Gilead
Fierce Biotech
Mon, 10/30/23 - 11:58 am
Merck KGaA
PARP inhibitors
Lynparza
Zejula
AstraZeneca
Gilead Sciences
solid tumors
Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data
Fierce Biotech
Wed, 10/11/23 - 10:20 am
Merck KGaA
evobrutinib
MS
multiple sclerosis
clinical trials
Merck KGaA doubles up on AI partners, tapping BenevolentAI and Exscientia for drug discovery push
Fierce Biotech
Wed, 09/20/23 - 08:37 am
Merck KGaA
drug discovery
artificial intelligence
BenevolentAI
Exscientia
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Mon, 08/7/23 - 10:32 am
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Merck KGaA invests €23 million to expand cell culture media production
Biopharma Reporter
Mon, 07/17/23 - 08:47 am
Merck KGaA
Kansas
cell culture
10 clinical trials to watch in the second half of 2023
BioPharma Dive
Wed, 06/28/23 - 11:44 am
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
The waxing and waning of the speedy approval
EP Vantage
Mon, 05/15/23 - 09:58 am
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Industry Seeks to Stimulate Innovation Through Grant Programs
BioSpace
Wed, 05/3/23 - 11:38 am
grants
R&D
Thermo Fisher Scientific
Merck KGaA
Qiagen
Finding the big spenders beyond big pharma
EP Vantage
Mon, 04/24/23 - 10:15 am
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals

Pages